MSC vs PRP for Premature Ovarian Insufficiency: what the registries show

Side by side

The condition underneath the comparison

Primary ovarian insufficiency is loss of ovarian function before forty, from genetic, autoimmune or iatrogenic causes. Cell and platelet-based 'ovarian rejuvenation' aims to restore folliculogenesis. Occasional spontaneous ovulation occurs in this condition — including spontaneous pregnancies — which is the fact most often exploited by uncontrolled case reports.

MSC: what it is

Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.

PRP: what it is

Platelet-rich plasma is a blood product, not a stem-cell product, though it is routinely sold as part of the same package. Preparation varies enormously between systems — platelet concentration, leukocyte content and activation all differ — so the label describes a category of procedure rather than a defined substance, which is the main reason its trial literature is so inconsistent.

Maturity difference

MSC has 0 Phase 3/4 records and 3 completed studies; PRP has 2 and 6. Where both sit early on the ladder, the honest answer to "which works better" is that registrations cannot tell you.

Leading MSC studies

Leading PRP studies

The honest comparison

Head-to-head trials putting these two approaches in the same protocol are rare or absent for most conditions. Comparing counts from separate registry queries shows where research effort went — driven by cost, regulation and sponsor interest as much as by biology. Anyone presenting one column of this table as proof of superiority is overreading it.

Frequently asked

Is MSC better than PRP for Premature Ovarian Insufficiency?

The registries cannot answer that. They show research volume and maturity, not comparative effectiveness: 18 vs 17 registered records (2026-08-29).

Which has more late-stage research for Premature Ovarian Insufficiency?

MSC: 0 Phase 3/4 records. PRP: 2.

Can a clinic offer both?

Some do, which is itself worth questioning — a provider offering every modality for every condition is describing a business model, not a treatment rationale.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.